Integrative Treatment: A Holistic Approach for Hyperparathyroidism

Learn about innovative approaches to integrative treatment for hyperparathyroidism that may support your health objectives.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. Over years of clinical practice at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, I have cared for many people whose vague fatigue, diffuse musculoskeletal pain, cognitive “brain fog,” and kidney stone histories were quietly driven by a calcium-regulating disorder: primary hyperparathyroidism. In this long-form educational post, I guide you through a clear, first-person journey—what hyperparathyroidism is, why calcium, vitamin D, and parathyroid hormone (PTH) matter, how to confirm the diagnosis rigorously, and how to choose between surgery and medical management in real-world settings. I explain secondary and tertiary hyperparathyroidism and the differential diagnosis of hypercalcemia, share actionable algorithms, and integrate the latest evidence from leading researchers using modern research methods.

This post also highlights our integrative model with Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), our Medical Director and Collaborative Physician with more than 40 years of experience. Together, we align internal medicine oversight with functional medicine, personal injury care, rehabilitation, and integrative chiropractic to protect bone and muscle function, optimize recovery, and ensure patient safety. I include detailed case stories from my practice, nuanced quality-of-life data, surgical indications, pharmacologic options like cinacalcet, and bone-protective therapies such as bisphosphonates and denosumab. Throughout, I use a narrative, evidence-based approach anchored in best-practice guidelines and cohort insights, and I weave in my clinical observations from pushasrx.com and my professional updates on LinkedIn to make complex physiology and decision-making both understandable and usable at the point of care.

Meet Our Integrative Team: Internal Medicine Oversight Meets Integrative Chiropractic

I practice at Injury Medical Clinic PA—also known as Mission Plaza Injury Medical Clinic—in El Paso, Texas. Our clinic is structured as a multidisciplinary, integrative practice where I combine chiropractic biomechanics, advanced practice nursing, and functional medicine with dedicated internal medicine oversight provided by our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933). Dr. Cardenas brings over four decades of adult medicine experience to our care pathways, which is pivotal when endocrine, renal, and metabolic complexities intersect with musculoskeletal health.

• What our multidisciplinary setup delivers:

• • Integrated diagnostics for hypercalcemia and hyperparathyroidism, including targeted lab panels and imaging.
  • Safe, MD-directed medication management, including cinacalcet and antiresorptives.
  • Chiropractic care tailored to bone density and fracture risk, emphasizing low-force techniques where appropriate.
  • Functional medicine support—nutrition, vitamin D optimization, hydration, and sleep—aligned with endocrine priorities.
  • Rehabilitation and personal injury care that protect mobility and reduce fall risk.
  • Coordinated endocrinology and surgical referrals, especially for parathyroidectomy.
  • Continuous patient education and shared decision-making.

Our model is common in integrative or injury care clinics: an MD provides medical direction while a chiropractor leads biomechanical care and functional rehabilitation. This integrated, patient-centered approach improves safety, clarity, and outcomes—especially for metabolic-bone disorders like primary hyperparathyroidism.

The Parathyroid Story: History, Anatomy, and Why These Tiny Glands Matter

• Anatomy highlights

• • Most people have four parathyroid glands, pea-sized nodules located behind the thyroid (two left, two right).
  • Their core job: regulate serum calcium via parathyroid hormone (PTH).

• A historical case that changed medicine

• • In 1926, Dr. Eugene DuBois identified hyperparathyroidism in Captain Charles Martel—a seaman whose devastating skeletal disease and recurrent urinary calculi (kidney stones) were ultimately due to a parathyroid adenoma. His case crystallized a core truth: when calcium regulation fails, the skeleton and kidneys can pay a steep price.

• Modern relevance

• • Today, we diagnose and manage hyperparathyroidism more effectively. Still, the core physiology is unchanged: the parathyroid glands’ autonomous overproduction of PTH drives chronic hypercalcemia, bone resorption, changes in renal calcium handling, and multisystem symptoms.

Calcium–PTH Physiology: The Feedback Loop That Defines Diagnosis

At the heart of hyperparathyroidism is the calcium–PTH feedback loop. Visualize a matrix where serum calcium (x-axis) is plotted against PTH (y-axis):

• Normal physiology
  • When calcium falls, PTH rises:

• • • Bone: increased resorption via osteoblast-mediated signaling to osteoclasts, releasing calcium.
    • Kidney: increased calcium reabsorption and phosphate excretion; stimulated 1-alpha-hydroxylase activity to convert 25-hydroxyvitamin D to calcitriol (1,25-dihydroxyvitamin D).
    • Gut: calcitriol boosts intestinal calcium absorption.

• • When calcium normalizes, PTH falls—a classic negative feedback mechanism.
• Primary hyperparathyroidism (PHPT)

• • High calcium with high or inappropriately normal PTH—the gland has “gone rogue,” producing PTH regardless of calcium level. The feedback loop is broken.
  • Clinically, this is the biochemical hallmark pointing to a parathyroid adenoma or multigland hyperplasia.

• Hypercalcemia of other causes
  • High calcium with low/suppressed PTH implicates non-parathyroid causes:

• • • Malignancy-related hypercalcemia via PTH-related peptide (PTHrP) or osteolytic metastases.
    • Excess vitamin D or vitamin A
    • Milk-alkali syndrome (high calcium carbonate use), thiazide diuretics, lithium, hyperthyroidism, adrenal insufficiency, granulomatous disease (e.g., sarcoidosis), lymphoma, immobilization, and TPN-related imbalances.

Understanding this matrix is foundational. In hypercalcemia, a “normal” PTH is inappropriately non-suppressed, and that abnormal pairing often points directly to PHPT.

The Three Pillars: Calcium, Vitamin D, and Parathyroid Hormone

Calcium: More Than Bone

• Key functions

• • Nerve and heart function (electrical signaling and contraction),
  • Muscle contraction,
  • Blood clotting.

• Total vs. ionized calcium

• • About 40–50% of total serum calcium is protein-bound, mostly to albumin. Low albumin can produce pseudohypocalcemia—a falsely low total calcium with normal ionized calcium.
  • We use corrected calcium formulas to adjust total calcium for albumin levels.
  • Ionized calcium is the biologically active fraction and often correlates more strongly with disease severity. It requires careful lab handling due to pH sensitivity.
  • Evidence suggests ionized calcium correlates closely with adenoma size, underscoring its clinical value in selected contexts (Norman & Politz, 2009).

Vitamin D: The Sunshine Hormone

• Sources

• • Skin synthesis via UVB exposure,
  • Diet and supplements.

• Activation pathway

• • Liver converts vitamin D to 25-hydroxyvitamin D (25[OH]D), the status marker.
  • Kidney converts 25[OH]D to 1,25-dihydroxyvitamin D (calcitriol). PTH stimulates this step.

• Forms

• • Vitamin D3 (cholecalciferol)—animal sources, skin production; typically more potent at raising 25[OH]D.
  • Vitamin D2 (ergocalciferol)—plant sources; common in 50,000 IU weekly prescriptions.

• Clinical importance

• • Calcitriol increases intestinal calcium absorption and reduces urinary calcium loss.
  • Adequate vitamin D is crucial for balanced calcium economy and to avoid secondary stimulation of PTH (Holick, 2007).

Parathyroid Hormone (PTH): The Master Regulator

• Regulation

• • Hypocalcemia stimulates PTH release,
  • Hypercalcemia suppresses PTH.

• Disease states

• • Hypoparathyroidism leads to hypocalcemia.
  • Hyperparathyroidism elevates PTH, causing hypercalcemia.

In primary hyperparathyroidism, one or more glands autonomously overproduce PTH, generating chronic hypercalcemia and downstream manifestations in bone, kidney, and neurocognitive domains (Bilezikian et al., 2018; Fraser, 2009).

Recognizing Hypercalcemia: From “Bones, Stones, Groans, and Psychic Moans” to Modern Presentations

• Mild hypercalcemia (calcium in the 10s mg/dL)

• • Often asymptomatic or subtle: fatigue, mood changes, mild cognitive difficulty.

• Moderate hypercalcemia (> 11 mg/dL)

• • Stones: polyuria, polydipsia, nocturia, and nephrolithiasis.
  • Groans: nausea, abdominal pain (common: constipation), anorexia.
  • Moans: confusion, lethargy, psychic changes.

• Severe hypercalcemia (> 12 mg/dL; crisis often ≥ 14 mg/dL)

• • Obtundation, acute kidney injury, severe dehydration, profound neurocognitive changes—a medical emergency.

• Chiropractic and functional medicine context

• • Patients frequently present with diffuse bone pain, proximal muscle weakness, chronic fatigue, and brain fog.
  • These systemic patterns prompt me to order a comprehensive metabolic panel and, if calcium is elevated, to consider hyperparathyroidism alongside musculoskeletal assessments.
  • Our integrative model allows me to relieve musculoskeletal pain safely while Dr. Cardenas confirms the endocrine diagnosis and directs medical management when indicated.

The Real-World Differential: Not All Hypercalcemia Is Hyperparathyroidism

When confronted with elevated calcium—particularly ≥ 12 mg/dL—I consider a broad differential:

• Malignancy-related hypercalcemia

• • PTHrP-mediated or osteolytic lesions; sometimes vitamin D–mediated in lymphomas (Bilezikian et al., 2018).

• Vitamin D toxicity

• • High-dose supplementation; elevated 25[OH]D and/or 1,25-dihydroxyvitamin D.

• Vitamin A toxicity

• • Chronic retinoid exposure increases bone turnover.

• Milk-alkali syndrome

• • Excess calcium carbonate (antacids) causing hypercalcemia, metabolic alkalosis, and renal dysfunction.

• Medications

• • Thiazides: increase renal calcium reabsorption.
  • Lithium: alters parathyroid CaSR set point, reduces calcium excretion.

• Endocrine/systemic conditions

• • Hyperthyroidism, adrenal insufficiency, sarcoidosis/granulomatous disease, lymphoma.

• Immobilization

• • Increased bone resorption and calcium efflux from bone.

• Total parenteral nutrition (TPN)

• • Electrolyte and vitamin D balance issues.

• Familial hypocalciuric hypercalcemia (FHH)

• • Lifelong mild hypercalcemia, low urinary calcium—vital to distinguish from PHPT because surgery does not correct FHH.

My first step is always to repeat the calcium—preferably fasting and with hydration optimized—and then add PTH, albumin, ionized calcium (when indicated), 25[OH]D, phosphorus, creatinine/eGFR, and a 24-hour urine calcium/creatinine to clarify the picture.

A Practical Diagnostic Pathway: Confirm Before You Image

Stepwise confirmation

• Verify abnormal calcium

• • Repeat serum calcium; correct for albumin or obtain ionized calcium.
  • Confirm persistence across two measurements.

• Measure PTH

• • In hypercalcemia, non-suppressed or elevated PTH strongly suggests PHPT.

• Rule out secondary causes and mimics.

• • Vitamin D status (25[OH]D): correct deficiency, recheck labs; low vitamin D can elevate PTH and complicate interpretation (Holick, 2007).
  • Renal function: CKD can elevate PTH; correlate with calcium, phosphate.
  • 24-hour urine calcium/creatinine: differentiates PHPT (normal to high urine calcium) from FHH (low urine calcium; CCCR < 0.01).
  • Assess medications and granulomatous diseases, especially if calcium is high and PTH is low/suppressed.

• End-organ evaluation

• • Bone: DEXA (lumbar spine, hip, femoral neck, distal one-third radius), consider vertebral fracture assessment (VFA) and trabecular bone score (TBS).
  • Kidney: creatinine/eGFR, renal ultrasound for nephrolithiasis/nephrocalcinosis (Cipriani et al., 2015).

• Localization imaging only after biochemical diagnosis

• • Neck ultrasound and sestamibi SPECT/CT for preoperative planning.
  • 4D-CT when first-line imaging is discordant or negative (AJR evidence suggests added value in challenging cases).
  • Remember: imaging does not diagnose PHPT; biochemistry does (Bilezikian et al., 2014; Eastell et al., 2019).

Interpreting Patterns: The Calcium–PTH Matrix in Clinical Language

• High calcium + high or inappropriately normal PTH

• • Primary hyperparathyroidism or tertiary hyperparathyroidism (if long-standing secondary disease, typically in CKD or post-transplant).

• Normal/low calcium + high PTH

• • Secondary hyperparathyroidism: vitamin D deficiency, CKD, malabsorption, low dietary calcium, certain medications.

• High calcium + low/suppressed PTH

• • Non-parathyroid causes: malignancy (PTHrP), vitamin D intoxication, granulomatous disease, milk-alkali, thiazides, lithium, endocrine disorders.

• Persistent normocalcemia + elevated PTH (on repeated testing)

• • Normocalcemic primary hyperparathyroidism (NPHPT)—diagnosis requires excluding secondary causes, ensuring normal renal function, vitamin D sufficiency, stable calcium intake, and medication confounders (Rolla & Fuleihan, 2018).

This matrix-based reasoning prevents premature imaging, avoids missed mimics, and channels patients toward the right therapy at the right time.

Primary, Secondary, and Tertiary Hyperparathyroidism: Definitions and Decision Points

• Primary hyperparathyroidism (PHPT)

• • Autonomous PTH secretion due to adenoma, multigland hyperplasia, or rarely carcinoma.
  • Most common modern presentation: asymptomatic hypercalcemia discovered via routine labs (Silverberg & Bilezikian, 2019).

• Secondary hyperparathyroidism

• • Appropriate PTH elevation in response to low/normal calcium due to CKD, vitamin D deficiency, malabsorption, or low calcium intake.
  • Treat the underlying cause: vitamin D repletion, phosphate control, diet optimization.

• Tertiary hyperparathyroidism

• • Autonomous PTH secretion after long-standing secondary hyperparathyroidism, often in CKD or post-renal transplant settings.
  • Both PTH and calcium are elevated.

Understanding the trajectory from secondary to tertiary helps clarify when surgery may be needed even outside classic PHPT scenarios.

When to Image: Bone, Kidney, and Preoperative Localization

• Bone health

• • DEXA: lumbar spine, hip, femoral neck, distal one-third radius (cortical site).
  • VFA/TBS: if available, add structural insights beyond density.

• Renal system

• • Renal ultrasound for stones or nephrocalcinosis; consider low-dose CT if clinically indicated.

• Parathyroid localization (for surgical planning)

• • Neck ultrasound and sestamibi SPECT/CT are first-line.
  • 4D-CT if first-line studies are equivocal or negative (AJR data support improved sensitivity in difficult cases).
  • Biochemical diagnosis comes first; imaging guides the surgeon.

“Cracking the Low Thyroid Code: A Comprehensive Assessment Guide”- Video

Surgical Indications: Evidence-Based Criteria and Patient Preferences

Surgery (parathyroidectomy) is the only curative therapy for PHPT. I align with international guidelines (Bilezikian et al., 2014; Eastell et al., 2019; Khan et al., 2017):

• Indications commonly accepted

• • Age < 50 years,
  • Serum calcium > 1.0 mg/dL above the upper limit of normal,
  • Kidney stones or nephrocalcinosis,
  • Reduced renal function (eGFR < 60 mL/min/1.73 m²) or significant decline,
  • Osteoporosis (T-score ≤ −2.5 at any site),
  • 24-hour urine calcium > 250 mg/day (women) or > 300 mg/day (men),
  • Fragility fractures or vertebral compression fractures.

• Patient preference matters

• • Even if criteria are not strictly met, many patients choose surgery after weighing bone, kidney, and symptom risks and the consistent benefits of biochemical cure.

• Why surgeon experience matters

• • Outcomes correlate with expertise and case volume; high-volume endocrine surgeons demonstrate 95–98% biochemical cure rates using minimally invasive approaches and intraoperative PTH monitoring (Udelsman et al., 2011).

What Surgery Delivers: Expectations, Risks, and Recovery

• Pathology

• • Single adenoma in ~80–90%,
  • Multigland involvement in ~15%,
  • Parathyroid carcinoma rare (~0.5–1%).

• Success metrics

• • Biochemical cure: normalization of calcium and PTH post-procedure.

• Benefits

• • Improved bone mineral density,
  • Reduced nephrolithiasis risk,
  • Stabilization of renal function trajectory,
  • Potential improvement in neurocognitive symptoms.

• Risks and considerations

• • Recurrent laryngeal nerve injury (≈1% permanent; ≈5% transient),
  • Bleeding/hematoma (~1 in 300),
  • Persistent/recurrent PHPT (~4–5%),
  • Hypocalcemia—transient paresthesias common; hungry bone syndrome in high-turnover disease states.

• Intraoperative PTH strategy

• • We look for a >50% drop in PTH within 10–15 minutes after excision to confirm target gland removal.

• Postoperative timeline

• • Short-term: monitor for hypocalcemia symptoms, adjust calcium/vitamin D.
  • Longer-term: check calcium and PTH at 6–12 weeks, then annually, and follow bone density per guidelines.

Watchful Waiting: What Long-Term Quality-of-Life Data Really Show

A 10-year prospective randomized controlled trial comparing parathyroidectomy vs. observation in asymptomatic PHPT provides nuanced insight (J Clin Endocrinol & Metab):

• Biochemical outcomes

• • Surgery group: cure; observation group: persistent abnormal labs.

• Quality-of-life findings

• • SF-36 vitality improved in the surgical group among eight subscales.
  • CPRS improved similarly in both groups.
  • Conclusion at 10 years: routine parathyroidectomy did not produce broad QoL superiority over observation in asymptomatic patients; observation did not degrade QoL.

• Clinical translation

• • Many asymptomatic patients do well with structured observation.
  • Surgery remains compelling when indications are met or when patient values favor definitive cure.
  • In my experience, some individuals feel dramatically better post-cure; averages in trials can obscure individual variability. Integrative rehabilitation can turn biochemical success into functional, felt improvements.

Geography and Vitamin D: Why Presentation Severity Varies Globally

Comparative cohort data from the United States and Beijing, China, highlight striking differences (Endocrine):

• U.S. cohort

• • Often asymptomatic hypercalcemia,
  • Average calcium ~10.4 mg/dL,
  • Modestly elevated PTH (~118 pg/mL ± 9),
  • Vitamin D insufficiency common (~21 ng/mL),
  • Radiological osteitis fibrosa cystica rare; kidney stones reduced from ~60% historically to ~15–20%.

• Beijing cohort

• • Younger average age (~37 years),
  • Higher calcium (~12 mg/dL),
  • PTH > 20× ULN frequently,
  • Severe vitamin D deficiency (~8.8 ng/mL),
  • Osteitis fibrosa cystica in ~60%; pathologic fractures (~35%); kidney stones (~42%).

• Clinical implications

• • Vitamin D deficiency and access to screening shape disease severity.
  • In high-risk populations, lower thresholds for bone and kidney imaging, proactive vitamin D strategies, and earlier intervention reduce complications.

Medical Management When Surgery Is Deferred or Contraindicated

When surgery is not pursued, our goals are to control serum calcium, protect the skeleton, minimize stone risk, and monitor proactively.

• Cinacalcet (Sensipar)

• • A calcimimetic that activates the calcium-sensing receptor (CaSR), suppressing PTH and lowering serum calcium.
  • Strength: reliably reduces calcium; useful in severe hypercalcemia or high-risk surgical cases.
  • Limitations: does not improve bone mineral density; GI side effects (nausea) are common; careful dose titration needed (typical starts at 30 mg BID; titrate to 90 mg BID as tolerated).
  • Precautions: consider QT risk, pregnancy nuances.

• Antiresorptives

• • Bisphosphonates (e.g., alendronate, zoledronic acid): improve bone density, counter PTH-driven resorption; zoledronic acid can acutely reduce severe hypercalcemia.
  • Denosumab: valuable in renal impairment; monitor carefully for hypocalcemia in severe deficiency.

• Vitamin D repletion

• • Aim for sufficiency (often 30–50 ng/mL) with careful titration to avoid exacerbating hypercalcemia.

• Hydration and lifestyle

• • Adequate fluids reduce stone risk and stabilize calcium.
  • Weight-bearing and resistance exercise support bone health.
  • Avoid excessive calcium supplements and assess antacid use.
  • Maintain dietary calcium (~1,000–1,200 mg/day) to avoid secondary PTH stimulation.

• Monitoring

• • Calcium, PTH, creatinine/eGFR every 3–6 months initially; adjust cadence as stability improves.
  • DEXA every 1–2 years.
  • Renal imaging as indicated.

Guidelines emphasize that medical therapy manages consequences; it does not cure the adenoma or autonomous gland function (Bilezikian et al., 2014; Khan et al., 2017; Silverberg & Bilezikian, 2018).

Normocalcemic Primary Hyperparathyroidism (NPHPT): A Subtle Subset

To diagnose NPHPT, I verify:

• Normal adjusted total and ionized calcium on repeated testing.
• Persistently elevated PTH on at least two occasions over 3–6 months.
• Exclusion of:

• • Vitamin D deficiency (e.g., 25[OH]D < 30 ng/mL),
  • Renal insufficiency (eGFR < 60),
  • Malabsorption or low calcium intake,
  • Medications (lithium, thiazides),
  • Other metabolic bone diseases (e.g., Paget’s).

These patients can still develop bone loss or stones; shared decision-making regarding surveillance vs. surgery is essential (Rolla & Fuleihan, 2018).

Familial and Early-Onset Clues: FHH and MEN Syndromes

• Familial hypocalciuric hypercalcemia (FHH)

• • Autosomal dominant, lifelong mild hypercalcemia, often low urinary calcium; CCCR < 0.01.
  • Surgery does not correct FHH—distinguishing it from PHPT is critical.

• MEN syndromes

• • Early-onset hyperparathyroidism (< 30 years), multigland disease: consider MEN1 or MEN2.
  • Genetic context shapes surgical planning and surveillance.

Integrative Chiropractic: Protecting Bone and Function Through Endocrine Treatment

Chiropractic care does not treat PHPT directly, but it is essential in our integrative method:

• During observation or medical management
  • Goals: reduce pain, protect bone, and preserve mobility and balance.
  • Techniques:

• • • Low-force spinal and extremity mobilizations when bone density is low,
    • Soft-tissue therapies for myofascial pain,
    • Neuromuscular re-education and proprioceptive training,
    • Personalized home programs for hip abductors, core, calf complex, intrinsic foot muscles, and postural endurance.

• • Precautions: avoid high-velocity thrusts in osteoporosis or fragility fractures.
• Preoperative conditioning

• • Gentle prehabilitation to improve functional reserve and support recovery.

• Postoperative recovery

• • Pain-modulated manual therapy, gradual strengthening, and balance training.
  • Monitoring for hypocalcemic symptoms and safe progression as labs normalize.

• Chronic nonoperative pathways

• • Consistent, gentle care reduces myofascial tension, sustains mobility, and complements medical therapy.

My clinical observations (shared on pushasrx.com and my LinkedIn profile) consistently show that careful, bone-safe manual therapy and progressive movement programs help turn biochemical stabilization into felt improvements in pain, energy, and function.

Functional Medicine Integration: Vitamin D, Hydration, Metabolic Health

Under Dr. Cardenas’s medical direction, our functional medicine lens addresses:

• Vitamin D optimization

• • Target individual sufficiency (commonly 30–50 ng/mL) while avoiding hypercalcemia exacerbation.

• Hydration

• • Daily fluid goals tailored to renal function and comorbidities, reducing stone risk and stabilizing calcium.

• Metabolic health

• • Address insulin resistance, dyslipidemia, sleep dysregulation, and weight—factors that intersect with bone metabolism and recovery capacity.
  • Evidence-based weight tools (e.g., GLP-1/GIP agonists) used under medical oversight; improving joint loads supports mobility.

• Nutrition and bone support

• • Focus on protein adequacy, magnesium, and dietary patterns that support bone; vitamin K2 reviewed in context but never a substitute for definitive endocrine care.

Functional medicine amplifies endocrine and surgical success by optimizing inputs that modulate bone, muscle, and resilience.

Team-Based Care in Action: Roles, Communication, and Safety

• Medical direction (Dr. Maria Guadalupe Cardenas, MD)

• • Oversees safety, guides complex lab interpretation, manages pharmacotherapy (e.g., cinacalcet, antiresorptives), and navigates referrals.
  • Provides internal medicine vigilance for oncologic, renal, and endocrine confounders.

• Integrative chiropractic and rehabilitation (Dr. Alex Jimenez, DC, APRN, FNP-BC)

• • Delivers bone-safe manual therapy, functional rehabilitation, and patient education; aligns movement plans with endocrine trajectories.

• Coordinated services

• • Physical therapy, nutrition support, and care coordination.
  • Shared decision-making, clear thresholds for surgical or pharmacologic escalation, standardized monitoring cadences.

• Why this model works

• • Safety: medication and bone density risks managed under MD oversight.
  • Efficiency: streamlined diagnostics, targeted referrals, fewer missed opportunities.
  • Patient experience: integrated biomechanics and medical precision improve adherence and outcomes.

Case Stories from Practice: Translating Protocols to People

Case 1: A 68-Year-Old Man With Cardiomyopathy and Biochemical PHPT

• Presentation

• • Calcium 10.8 mg/dL; PTH 158 pg/mL (prior 190 pg/mL),
  • Vitamin D 16.3 ng/mL (low),
  • 24-hour urine calcium 364 mg (elevated for a male),
  • eGFR 63.4 mL/min/1.73 m².
  • DEXA: normal T-scores,
  • Neck ultrasound: left posterior 12 × 20 × 11 mm nodule suspicious for adenoma.

• Comorbidities

• • Non-obstructive coronary disease, non-ischemic cardiomyopathy, chronic systolic heart failure, atrial fibrillation.

• Why I recommended surgery

• • Persistent hypercalcemia, elevated urine calcium, localizable adenoma, renal risk, and age considerations; patient desired definitive cure.

• Intraoperative PTH

• • Baseline 533 pg/mL; dropped to 69 at 5 min, 49 at 10 min, 42 at 15 min—confirming success.

• Post-op

• • Calcium normalized to 9.4 mg/dL; PTH initially above lab reference then improved as vitamin D rose (to 19 ng/mL).
  • Immediate subjective improvement in energy; returned to golfing.

• Integrative elements

• • Medical oversight ensured cardiopulmonary safety.
  • Rehab and low-force chiropractic focused on safe mobilization and graded activity, aligning with cardiac status and endocrine recovery.
  • Functional medicine targeted gentle vitamin D repletion, hydration, and sleep.

Case 2: An 85-Year-Old Woman With Severe Hypercalcemia, Nonoperative Pathway

• Presentation

• • ER calcium 15.8 mg/dL; treated acutely with fluids, calcitonin, bisphosphonate; malignancy excluded.
  • Chronic dementia; family declined surgery.

• Course

• • Labs ranged: calcium 9.6–12+, PTH 147–201; intermittent hypercalcemic crises despite cinacalcet escalated to 90 mg BID.
  • Zoledronic acid used as rescue during spikes; careful renal monitoring.

• Plan

• • Values-focused care: avoid hospitalizations where possible, maintain hydration, family education to notice subtle cognitive changes signaling calcium spikes, and coordinate rescue therapy.

• Integrative elements

• • Gentle mobility, seated exercises, caregiver-supported transfers.
  • Nutrition support to maintain protein intake and prevent dehydration-driven constipation.

• Clinical lesson

• • Appearance can mislead; severe numbers may coexist with subtle symptoms. Frequent labs and caregiver training are lifesaving.

Case 3: A 57-Year-Old Pilot With Foot Pain, Hypercalcemia, and Curative Surgery

• Presentation

• • Calcium 10.5–11.5 mg/dL; PTH ~107–111 pg/mL; vitamin D ~43 ng/mL.
  • DEXA normal; 24-hr urine calcium 184 mg (normal).
  • Neck ultrasound identified a TI-RADS 4 thyroid nodule (benign FNA); renal ultrasound showed a non-obstructing stone.

• Management

• • Proceeded to parathyroidectomy; adenoma excised.
  • Post-op: calcium 9.7 mg/dL; PTH 32 pg/mL; eGFR improved to 70.

• Outcome

• • Chronic foot aching largely resolved immediately post-op—likely due to normalized neuromuscular excitability and reduced inflammatory sensitization.

• Integrative follow-up

• • Gait analysis, custom orthotics where appropriate, foot/ankle mobility and strengthening, low-force chiropractic techniques along the kinetic chain, and functional medicine support for weight and sleep.

These stories show how evidence and integrative care translate into meaningful, personalized results. They also illustrate why we never rely solely on lab values—context and a coordinated plan matter.

Bone Pain, Fatigue, and Brain Fog: Why PHPT Feels the Way It Does

• Bone turnover and pain

• • Chronic PTH elevation increases resorption and releases cytokines that sensitize pain pathways; early microarchitectural changes may not show on DEXA but can still cause aches.

• Neuromuscular and cognitive

• • Hypercalcemia dampens neuronal excitability, contributing to fatigue, concentration difficulties, and mood changes.
  • Dehydration (common with hypercalcemia) worsens orthostasis and fatigue.

• Recovery trajectory

• • Some patients feel immediate relief after cure; others experience gradual improvement as bone remodeling stabilizes over months to years.
  • Bone density typically improves over 1–2 years, often most at the lumbar spine and hip; cortical sites (e.g., distal radius) can track more variably.

• Integrative rehab

• • Gentle, progressive programs restore mobility and reduce fall risk.
  • Manual therapy relieves myofascial tension; balance training protects during calcium fluctuations or postoperative phases.

Safety First: Special Situations and Precautions

• Severe hypercalcemia (≥ 14 mg/dL)

• • Medical emergency: IV fluids, calcitonin, IV bisphosphonate or denosumab; identify triggers.

• Renal impairment

• • Tailor therapy; denosumab may be preferred for bone protection in significant CKD.

• Osteoporosis and fragility fractures

• • Avoid high-velocity manipulations; prioritize low-load strengthening and fall prevention.

• Postoperative hypocalcemia

• • Paresthesias around mouth/fingers signal low calcium; ensure supplementation plan and response protocol.

• Polypharmacy review

• • Diuretics, lithium, vitamin A/D dosing, antacids—coordinate deprescribing when appropriate.

• Pregnancy and lactation

• • Rare but critical: specialist input for maternal/fetal safety; hydration and calcium management require meticulous oversight.

Monitoring Framework: How We “Watch and Wait” Responsibly

For asymptomatic patients without surgical indications:

• Every 6 months initially

• • Serum calcium and PTH,
  • Creatinine/eGFR,
  • Symptom review (fatigue, mood, cognition, bone pain).

• Annually

• • DEXA (annually for high risk; every 1–2 years otherwise),
  • Renal imaging if stone symptoms develop or prior stones were present.

• Lifestyle

• • Hydration goals, vitamin D targets, weight-bearing and strengthening exercises.

• Escalation triggers

• • Calcium rises > 1 mg/dL over upper normal,
  • New kidney stones or significant hypercalciuria,
  • DEXA declines to osteoporosis or fragility fracture occurs,
  • Patient preference shifts to definitive cure.

Documentation and team communication ensure timely action and continuity.

Point-of-Care Workflow: A Playbook You Can Use

• Step 1: Confirm hypercalcemia with repeat fasting serum calcium; check albumin and/or ionized calcium.
• Step 2: Order PTH. If high or inappropriately normal with elevated calcium, suspect PHPT; if high with normal/low calcium, investigate secondary causes.
• Step 3: Obtain 25[OH]D, phosphorus, creatinine/eGFR, and 24-hour urine calcium/Cr.
• Step 4: Exclude FHH if low urinary calcium and CCCR < 0.01.
• Step 5: Assess bone (DEXA, distal radius) and renal status (ultrasound).
• Step 6: Decide on surgery vs. medical management based on indications and preferences.
• Step 7: If surgery planned, perform localization imaging (ultrasound, sestamibi; consider 4D-CT).
• Step 8: If medical management, set monitoring cadence, consider cinacalcet for calcium control, and initiate bone-protective therapy as appropriate.
• Step 9: Implement integrative rehabilitation and chiropractic care to support bone, muscle, and function safely.
• Step 10: Educate continuously—hydration, activity, supplement caution, and follow-up adherence.

This structured approach maps evidence to real practice and naturally aligns our multidisciplinary team.

Patient Education Highlights: Clear Messages That Change Outcomes

• Not all elevated calcium is PHPT; confirm with repeat labs and PTH.
• Hydration is therapy—it reduces stone risk and stabilizes calcium.
• Do not eliminate dietary calcium; aim for a balanced intake to avoid secondary PTH elevation.
• Vitamin D optimization matters but must be done cautiously.
• Integrative care—medicine and movement—turn biochemical stabilization into felt improvements in energy, pain, and function.
• Be transparent about OTCs and supplements—antacids count.
• Follow lab schedules; trending values guide plan changes and keep you safe.

These points help patients navigate safely and confidently.

Frequently Asked Questions

• If my calcium is only slightly high, do I really have PHPT?

• • If calcium is persistently high and PTH is not suppressed, PHPT is likely. We confirm with repeated labs and a structured workup.

• Can vitamin D supplementation cure PHPT?

• • Vitamin D can lower PTH somewhat and improve bone health, but it does not remove an adenoma. We replete carefully to avoid worsening hypercalcemia.

• Will surgery fix my fatigue and aches?

• • Many patients feel better, but not all. QoL research shows variable benefits beyond vitality. Our integrative approach addresses other contributors to fatigue to maximize improvement.

• Can I wait and watch?

• • Yes, if you do not meet surgical criteria and agree to structured monitoring. We will act if risks escalate.

• Is chiropractic safe when bone density is low?

• • Yes, with modifications. We avoid high-velocity thrusts in osteoporotic bone and emphasize low-force, joint-sparing techniques, strengthening, and balance.

Clinical Observations and Public Education

I share clinical observations and patient education resources regularly:

• pushasrx.com: case narratives, integrative strategies, rehab insights.
• linkedin.com/in/dralexjimenez/: ongoing professional updates and community education.

Patients with hyperparathyroidism and bone fragility benefit from coordinated plans that blend conservative musculoskeletal care with endocrine management. As serum calcium normalizes—through surgery or medical therapy—exercise tolerance often improves, enabling progressive loading to rebuild bone and restore function.

Closing Reflections: Evidence, Experience, and Empathy

Hyperparathyroidism is a condition where modern evidence and thoughtful clinical judgment align. Ten-year randomized data reassure us that watchful waiting is safe for many asymptomatic patients. Surgery offers definitive cure and consistent biochemical wins for those who meet indications or choose it by preference. Functional and rehabilitative strategies turn those biochemical wins into better daily life—more mobility, less pain, reduced fall risk.

With Dr. Maria Guadalupe Cardenas, MD guiding medical safety and complex decision-making, and with integrative chiropractic, functional nutrition, and rehabilitation under one roof, our team is dedicated to clear diagnostics, patient-centered care, and practical relief. If you or someone you care for is navigating elevated calcium or suspected hyperparathyroidism, we are here to help you make sense of the science and choose the right path forward.

References

• Bilezikian, J. P., Bandeira, L., Khan, A., & Cusano, N. E. (2018). Hyperparathyroidism. The Lancet, 391(10116), 168–178.
• Fraser, W. D. (2009). Hyperparathyroidism. The Lancet, 374(9684), 145–158.
• Holick, M. F. (2007). Vitamin D deficiency. New England Journal of Medicine, 357(3), 266–281.
• Norman, J., & Politz, D. (2009). The role of ionized calcium in the diagnosis and management of primary hyperparathyroidism. Endocrine Practice, 15(3), 226–230.
• Silverberg, S. J., & Bilezikian, J. P. (2019). The diagnosis and management of asymptomatic primary hyperparathyroidism. Nature Clinical Practice Endocrinology & Metabolism, 4(3), 146–156.
• Bilezikian, J. P., Brandi, M. L., Eastell, R., Silverberg, S. J., Udelsman, R., Marcocci, C., & Potts, J. T. Jr. (2014). Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the Fourth International Workshop. Journal of Clinical Endocrinology & Metabolism.
• Eastell, R., Brandi, M. L., Costa, A. G., D’Amour, P., Shoback, D. M., & Thakker, R. V. (2019). Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop. Journal of Clinical Endocrinology & Metabolism.
• Khan, A. A., Hanley, D. A., Rizzoli, R., Bollerslev, J., Young, J. E. M., Rejnmark, L., et al. (2017). Primary hyperparathyroidism: Review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporosis International.
• Marcocci, C., Cetani, F., Rubin, M. R., Silverberg, S. J., & Bilezikian, J. P. (2014). Parathyroid hormone and bone. Endocrinology and Metabolism Clinics of North America.
• Cipriani, C., Biamonte, F., Costa, A. G., Zhang, C., Bilezikian, J. P., & Minisola, S. (2015). Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. Journal of Clinical Endocrinology & Metabolism.
• Yeh, M. W., Ituarte, P. H. G., Zhou, H. C., Nishimoto, S., Liu, I.-L. A., Harari, A., et al. (2013). Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. Journal of Clinical Endocrinology & Metabolism.
• Udelsman, R., Lin, Z., & Donovan, P. (2011). The superiority of minimally invasive parathyroidectomy. JAMA Surgery.
• Rolla, A. R., & Fuleihan, G. E.-H. (2018). Normocalcemic primary hyperparathyroidism. Current Osteoporosis Reports.
• Pretorius, M. et al. (2020). Effect of parathyroidectomy versus observation on long-term quality of life in asymptomatic primary hyperparathyroidism: 10-year results from a prospective randomized controlled trial. Journal of Clinical Endocrinology & Metabolism.
• Endocrine (Global variations in PHPT presentation and severity; U.S. vs. Beijing). Primary hyperparathyroidism: Global variations in presentation and severity.
• 4D-CT and advanced localization in challenging PHPT cases.
• JAMA/Osteoporosis International. Cinacalcet for PHPT: effects on calcium and PTH; limits on bone density changes and Bisphosphonates and denosumab in PHPT: skeletal effects without biochemical cure.
• European Journal of Endocrinology. Hungry bone syndrome after parathyroidectomy: mechanisms and management.
• Journal of Renal Nutrition. Nephrolithiasis in PHPT: modern risk and prevention.

SEO tags: hyperparathyroidism, primary hyperparathyroidism, secondary hyperparathyroidism, tertiary hyperparathyroidism, parathyroid hormone, PTH, calcium, vitamin D, ionized calcium, cinacalcet, Sensipar, parathyroidectomy, minimally invasive parathyroidectomy, sestamibi, 4D-CT, bone density, DEXA, trabecular bone score, vertebral fracture assessment, osteoporosis, nephrolithiasis, kidney stones, familial hypocalciuric hypercalcemia, MEN1, MEN2, internal medicine oversight, integrative chiropractic, functional medicine, rehabilitation, hydration therapy, El Paso, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr. Maria Guadalupe Cardenas, Dr. Alex Jimenez, pushasrx.com, Dr. Alex Jimenez LinkedIn